Episodes
-
380: A new top drug regulator and the future of psychedelics
Not summarized yet
-
379: How Mark Cuban plans to ‘f— up’ health care
Not summarized yet
-
378: Merck's heart disease win and the FDA's new drug regulator
Not summarized yet
-
377: Melodrama at the FDA and the Pfizer-Novo bidding war
Not summarized yet
-
376: BridgeBio’s great week and Moderna’s unraveling
Not summarized yet
-
375: Startups push the FDA and biotech booms in North Carolina
Not summarized yet
-
374: Veteran biotech executive Clive Meanwell on drug pricing and the obesity market
Not summarized yet
-
373: Party in biotech land and AstraZeneca’s miscalculation
Not summarized yet
-
372: A pharma C-suite shakeup and Trump's deal with Pfizer
Not summarized yet
-
371: A gene therapy success in Huntington's and Trump's autism announcement
Not summarized yet
-
370: Pharma sours on the U.K., plus biotech M&A's quiet roll
Not summarized yet
-
369: Trump, Chinese biotech, and an industry career reshaped by illness
Not summarized yet
-
368: New stakes in the vaccine dispute and a boost for biotech
Not summarized yet
-
367: The ouster of CDC's director, biotech venture firm rankings
Not summarized yet
-
366: Viking’s obesity flop, ‘pharma to table’ drug sales
Not summarized yet
-
365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended
Not summarized yet
-
364: Closing a zombie biotech, and Lilly's disappointing obesity readout
Not summarized yet
-
363: What Vinay Prasad’s ouster means for biotech and the FDA
Not summarized yet
-
362: A mother’s perspective on Sarepta’s gene therapy halt
Not summarized yet
-
361: Inside an FDA drug rejection, and layoffs at Sarepta
Not summarized yet
Follow this show on AudioBrevity and new episodes get summarized for you. Create a free account